AstraZeneca's triplet combo succeeds in some liver cancer patients

AstraZeneca's triplet combo succeeds in some liver cancer patients

AstraZeneca presented at ASCO 2026 phase trial data showing a triplet regimen — one targeted therapy plus two immunotherapies — improves outcomes in a subset of liver cancer patients. For biopharma-adjacent tech and health AI teams, the combo approach signals that oncology pipelines are shifting toward multi-modal protocols, increasing demand for biomarker-driven patient stratification and real-world data infrastructure.